The pharmaceutical company Grifols—has started dosing patients in the final stage (Phase 3) of two clinical trials. The company is trying to get approval to use two of its antibody-based…
As reported by PharmaBiz, Eli Lilly and Company has announced positive findings from its Phase 3 BRUIN CLL-322 trial evaluating pirtobrutinib (Jaypirca), a next-generation non-covalent Bruton tyrosine kinase (BTK) inhibitor,…
AbbVie has announced a landmark regulatory milestone with the US FDA's approval of a supplemental new drug application (sNDA) for the combination of Venclexta (venetoclax) and acalabrutinib as a first-line…
Eli Lilly presented compelling clinical evidence positioning its BTK inhibitor Jaypirca as a potentially superior treatment option compared to the established blood cancer therapy Imbruvica, marking a significant competitive shift…
Recent research has brought to light striking genetic differences in chronic lymphocytic leukemia (CLL) among African American (AA) patients, suggesting that their disease may follow a distinct course compared to…
In January 2023, the U.S. FDA approved Jaypirca (pirtobrutinib) for the treatment of adults with relapsed or refractory mantle cell lymphoma who had previously undergone two lines of systemic…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Rare Community Profiles Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
According to a story from Medpage Today, a study conducted by scientists at the University of Texas MD Anderson Cancer Center highlighted the substantial benefits of aerobic exercise in people…
In Jordyn Sava's reporting from Targeted Oncology, readers learn that the U.S. Food and Drug Administration (FDA) granted clearance to a global Phase 3 study. This means that the…
At the start of October 2022, biopharmaceutical company Mustang Bio, Inc. shared via news release that the first patient was treated in a study of MB-106. Within the study,…
The most common form of leukemia in Western countries is chronic lymphocytic leukemia (CLL). The disease accounts for almost thirty percent of known leukemia cases. Approximately 30,000 Europeans were…
Leukemia, in general terms, is a form of cancer that affects the bone marrow and blood cells. According an article in Medical News Today, leukemia is categorized in accordance…
On May 26, 2022, biopharmaceutical company Nurix Therapeutics, Inc. ("Nurix") shared via news release that positive data was available from an ongoing Phase 1a dose escalation study. Within the study,…
According to a press release that can be found on AP News, new data have been released on a potential treatment - called NVG-111 - for both mantle cell lymphoma…
Roger Bliss, 68-year-old pulmonary hypertension (PH) patient, was diagnosed with chronic lymphocytic leukemia and small lymphocytic lymphoma. In addition, Roger has celiac disease. He recently interviewed with Pulmonary Hypertension News.…
The FDA has just announced that they are reevaluating their approvals for Ukoniq. This reevaluation comes after study findings which demonstrated there may be an increased risk of fatality for…
A recent study examined the impact of age on clinical outcomes for patients diagnosed with chronic lymphocytic leukemia (CLL). This study was published in the journal Blood Advances. All patients in…
According to a recent article, after the results of a clinical trial, researchers have proven that CAR-T cells can cure patients that are diagnosed with leukemia. Leukemia Leukemia is a…
Targeted Oncology recently featured a discussion by Dr. Jennifer Brown, director of Dana Farber’s Chronic Lymphocytic Leukemia Center, on the interim results from the SEQUOIA Phase 3 trial. The trial…
Dr. Deborah M. Stephens from the Huntsman Cancer Institute recently presented at the 39th Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow (CFS). The presentation surrounded how critical identifying…
According to a recent article, a study looking at an investigational BTK degrader proved to have important results in patients with chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic…
According to a news release from biotechnology company LAVA Therapeutics N.V. ("LAVA"), the company's therapeutic candidate LAVA-051 recently earned Orphan Drug designation from the FDA. The therapy is designed for…
The 2021 Society for Hematological Oncology (SOHO) Annual Meeting took place last month from September 8-11, 2021. During the meeting, researchers discussed new advances in the field of hematology. According…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
